Novel Therapies in Melanoma

Global cancer statistics

2011 • 55,498 citations

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

2010 • 14,016 citations

Cancer Statistics, 2010

2010 • 12,557 citations

Mutations of the BRAF gene in human cancer

2002 • 10,249 citations

Signaling by intrathymic cytokines, not T cell antigen receptors, specifies CD8 lineage choice and promotes the differentiation of cytotoxic-lineage T cells

2010 • 5,969 citations

Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases.

1995 • 5,124 citations

EGFRMutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib

2005 • 3,807 citations

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

2010 • 3,500 citations

Targeting RAS signalling pathways in cancer therapy

2003 • 3,105 citations

Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria

2009 • 3,044 citations

Patterns of somatic mutation in human cancer genomes

2007 • 2,975 citations

Cancer immunotherapy: moving beyond current vaccines

2004 • 2,932 citations

Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4

1995 • 2,842 citations

Final Version of the American Joint Committee on Cancer Staging System for Cutaneous Melanoma

2001 • 2,658 citations

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

2010 • 2,120 citations

High-Dose Recombinant Interleukin 2 Therapy for Patients With Metastatic Melanoma: Analysis of 270 Patients Treated Between 1985 and 1993

1999 • 1,967 citations

Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

1998 • 1,826 citations

High frequency of BRAF mutations in nevi

2002 • 1,701 citations

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation

2010 • 1,438 citations

Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF

2010 • 1,404 citations

BRAF mutation predicts sensitivity to MEK inhibition

2005 • 1,312 citations

Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity

2008 • 1,305 citations

Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K

2010 • 1,218 citations

Combination Immunotherapy of B16 Melanoma Using Anti–Cytotoxic T Lymphocyte–Associated Antigen 4 (Ctla-4) and Granulocyte/Macrophage Colony-Stimulating Factor (Gm-Csf)-Producing Vaccines Induces Rejection of Subcutaneous and Metastatic Tumors Accompanied by Autoimmune Depigmentation

1999 • 1,000 citations

gp100 Peptide Vaccine and Interleukin-2 in Patients with Advanced Melanoma

2011 • 849 citations

Antitumor Activity in Melanoma and Anti-Self Responses in a Phase I Trial With the Anti-Cytotoxic T Lymphocyte–Associated Antigen 4 Monoclonal Antibody CP-675,206

2005 • 584 citations

Global perspectives of contemporary epidemiological trends of cutaneous malignant melanoma

2004 • 573 citations

Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral, Small-Molecule Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor AZD6244 (ARRY-142886) in Patients With Advanced Cancers

2008 • 569 citations

Results of a Phase III, Randomized, Placebo-Controlled Study of Sorafenib in Combination With Carboplatin and Paclitaxel As Second-Line Treatment in Patients With Unresectable Stage III or Stage IV Melanoma

2009 • 546 citations

Elevated CRAF as a Potential Mechanism of Acquired Resistance to BRAF Inhibition in Melanoma

2008 • 500 citations

Principles and use of anti-CTLA4 antibody in human cancer immunotherapy

2006 • 437 citations

Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer

1997 • 383 citations

CTLA-4 Blockade Reverses CD8+ T Cell Tolerance to Tumor by a CD4+ T Cell– and IL-2-Dependent Mechanism

1999 • 287 citations

Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors.

2010 • 278 citations

CCI‐779 in metastatic melanoma

2005 • 227 citations

Phosphoinositide 3-kinase in disease: timing, location, and scaffolding

2005 • 211 citations

The First-in-Human Study of the Hydrogen Sulfate (Hyd-Sulfate) Capsule of the MEK1/2 Inhibitor AZD6244 (ARRY-142886): A Phase I Open-Label Multicenter Trial in Patients with Advanced Cancer

2010 • 202 citations

Enhanced induction of antitumor T-cell responses by cytotoxic T lymphocyte-associated molecule-4 blockade: the effect is manifested only at the restricted tumor-bearing stages.

1997 • 197 citations

Targeting the MAPK pathway in melanoma: Why some approaches succeed and other fail

2010 • 195 citations

Phase III, open-label, randomized, comparative study of tremelimumab (CP-675,206) and chemotherapy (temozolomide [TMZ] or dacarbazine [DTIC]) in patients with advanced melanoma

2008 • 159 citations

Ordered phosphorylation of p42^mapk by MAP kinase kinase

1992 • 159 citations

AZD6244 (ARRY-142886) vs temozolomide (TMZ) in patients (pts) with advanced melanoma: An open-label, randomized, multicenter, phase II study

2008 • 131 citations

Phase I/II study to assess safety, pharmacokinetics, and efficacy of the oral MEK 1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral BRAF inhibitor GSK2118436 (GSK436).

2011 • 123 citations

Safety and efficacy results from the first-in-human study of the oral MEK 1/2 inhibitor GSK1120212.

2010 • 121 citations

Synergistic inhibition of human melanoma proliferation by combination treatment with B-Raf inhibitor BAY43-9006 and mTOR inhibitor Rapamycin

2005 • 111 citations

Identification of a Novel Mitogen-Activated Protein Kinase Kinase Activation Domain Recognized by the Inhibitor PD 184352

2002 • 68 citations

Results of a multicenter, randomized, double‐blind phase 2/3 study of lenalidomide in the treatment of pretreated relapsed or refractory metastatic malignant melanoma

2009 • 50 citations

Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF inhibitor vemurafenib with dacarbazine (DTIC) in patients with ^V600EBRAF-mutated melanoma.

2011 • 26 citations

Phase I/II study to assess safety, pharmacokinetics, and efficacy of the oral MEK 1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral BRAF inhibitor GSK2118436 (GSK436).

2011 • 20 citations

Phase III randomized study of ipilimumab (IPI) plus dacarbazine (DTIC) versus DTIC alone as first-line treatment in patients with unresectable stage III or IV melanoma.

2011 • 18 citations